219.90 0.00 (0.00%)
After hours: 5:10PM EDT
|Bid||215.25 x 200|
|Ask||227.00 x 100|
|Day's Range||218.95 - 221.09|
|52 Week Range||175.66 - 248.39|
|PE Ratio (TTM)||170.73|
|Forward Dividend & Yield||3.00 (1.37%)|
|1y Target Est||N/A|
Apax Partners acquired a majority stake in Vyaire Medical, which previously was Becton Dickinson’s respiratory services business, in October 2016, with Becton Dickinson retaining a minority stake in the ...
Moody's Investors Service, ("Moody's") assigned a B3 Corporate Family Rating (CFR) and B3-PD Probability of Default Rating (PDR) to Vyaire Medical, Inc ("Vyaire"). Moody's also assigned ...
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
With a presence across 10 markets, leadership in some segments and a "robust" product pipeline, Becton Dickinson and Co (NYSE: BDX ) is "more than just needles and syringes," according ...
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
Johnson & Johnson (JNJ) began trading ex-dividend on February 26, 2018. It will pay a dividend of $0.84 per share on March 13, 2018, to shareholders of record as of February 26, 2018. Dividend aristocrats are companies that have been paying their shareholders consistently increasing dividends for at least 25 years.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.